Gilead Sciences Announces Positive Phase 2 Results for Twice-Yearly Lenacapavir and Advances Long-Acting HIV Prevention and Treatment at EACS 2025
Reuters
Oct 15
<a href="https://laohu8.com/S/GILD">Gilead</a> Sciences Announces Positive Phase 2 Results for Twice-Yearly Lenacapavir and Advances Long-Acting HIV Prevention and Treatment at EACS 2025
Gilead Sciences Inc. has announced its upcoming participation in the 20th European AIDS Conference (EACS) to be held in Paris, France, from October 15-18, 2025. The company will present new scientific data from its HIV research and development programs, including updates on clinical studies and strategic initiatives. Among the highlights is the Phase 2 PURPOSE 5 trial, which evaluates the use of twice-yearly lenacapavir for HIV pre-exposure prophylaxis (PrEP) in high-priority populations in France and the UK who have not previously used PrEP. Additionally, late-breaking 96-week outcomes from a Phase 2 study of an investigational, once-weekly oral combination of islatravir and lenacapavir will be presented, showing maintenance of viral suppression in people living with HIV. Results from these studies are scheduled to be presented at the EACS 2025 conference.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251015972388) on October 15, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.